1123925

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549



SECTION 4(6), AND/OR

UNIFORM LIMITED OFFERING EXEMPTION



SEC USE ONLY						
Prefix	1	Serial				
	DATE RECEI	VED				

Name of Offering (check if this is an amendment and name has changed, and indicate change.) Sale of units consisting of common stock and warrants									
Filing under (Check box(es) that apply): ☐ Rule 504 ☐ R Type of Filing: ☐ New Filing ☐ Amendment	ule 505 🛛 Rule 506	Section 4(6)	LOE						
A. BASIC IDENTIFICATION DATA									
Enter the information requested about the issuer									
Name of Issuer (check if this is an amendment and name ha Novelos Therapeutics, Inc.	s changed, and indicat	te change.)							
Address of Executive Offices (Number and Street, City, Sta One Gateway Center, Suite 504, Newton, MA 02458	[· · · · · · · · · · · · · · · · · · ·								
Address of Principal Business Operations (Number and Street, City, State, Zip Code) (if different from Executive Offices) Telephone Number (Including Area Code)									
Brief Description of Business Development stage company established to commercialize di	rugs for the treatmen	t of cancer and hepatitis	· [PROCES	— SED				
Type of Business Organization									
□ Corporation □ Iimited partnership, alrea	ady formed	other (please specify):	R	JUN 152	2005				
☐ business trust ☐ limited partnership, to be	e formed			THOMSO	100				
Actual or Estimated Date of Incorporation or Organization: MONTH YEAR									
· · · · · · · · · · · · · · · · · · ·	CN for Canada; FN for other foreign jurisdiction)								

General Instructions

Federal:

Who Must File: All issuers making an offering of securities in reliance on an exemption under Regulation D or Section 4(6), 17 CFR 230.501 et seg. or 15 U.S.C. 77d(6).

When To File: A notice must be filed no later than 15 days after the first sale of securities in the offering. A notice is deemed filed with the U.S. Securities and Exchange Commission (SEC) on the earlier of the date it is received by the SEC at the address given below or, if received at that address after the date on which it is due, on the date it was mailed by United States registered or certified mail to that address.

Where to File: U.S. Securities and Exchange Commission, 450 Fifth Street, N.W., Washington, D.C. 20549.

Copies Required: Five (5) copies of this notice must be filed with the SEC, one of which must be manually signed. Any copies not manually signed must be photocopies of the manually signed copy or bear typed or printed signatures.

Information Required: A new filing must contain all information requested. Amendments need only report the name of the issuer and offering, any changes thereto, the information requested in Part C, and any material changes from the information previously supplied in Parts A and B. Part E and the Appendix need not be filed with the SEC.

Filing Fee: There is no federal filing fee.

State:

This notice shall be used to indicate reliance on the Uniform Limited Offering Exemption (ULOE) for sales of securities in those states that have adopted ULOE and that have adopted this form. Issuers relying on the ULOE must file a separate notice with the Securities Administrator in each state where sales are to be, or have been made. If a state requires the payment of a fee as a precondition to the claim for the exemption, a fee in the proper amount shall accompany this form. This notice shall be filed in the appropriate states in accordance with state law. The Appendix to the notice constitutes a part of this notice and must be completed.

ATTENTION

Failure to file notice in the appropriate states will not result in a loss of the federal exemption. Conversely failure to file the appropriate federal notice will not result in a loss of an available state exemption unless such exemption is predicated on the filing of a federal notice.

SEC 1972 (6-				ormation contained in this f a currently valid OMB con		1 of 8
020 10/2 10	02)	quired to respon		TIFICATION DATA	inornamber.	1010
2. Enter th	power to vote of	of the issuer, if or dispose, or di	the issuer has been or rect the vote or disposit	tion of, 10% or more of	a class of equity s	
•	issuers; and		ector of corporate issue artnership of partnershi	rs and of corporate gen	neral managing pa	rtners of partnership
Check Box(es		☐ Promoter	☐ Beneficial Owner		☑ Director	☐ General and/or Managing Partner
Full Name (La Harry S. Pa	ast name first, if ind Imin	ividual)	_			
	Residence Address Therapeutics,		and Street, City, State, Zi way Center, Suite 504		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
Check Box(es		Promoter	☐ Beneficial Owner		□ Director	☐ General and/or Managing Partner
Full Name (La Simyon Pal	ast name first, if ind min	·				
	Residence Address Therapeutics,		and Street, City, State, Zi way Center, Suite 504			
Check Box(es		☐ Promoter	☐ Beneficial Owner	☐ Executive Officer	□ Director	☐ General and/or Managing Partner
Full Name (La Mark Balazo	ist name first, if ind ovsky	ividual)				
	lesidence Address Therapeutics,	(Number Inc., One Gate	and Street, City, State, Zi way Center, Suite 504	p Code) , Newton, MA 02458		
Check Box(es		☐ Promoter	☐ Beneficial Owner	☐ Executive Officer		☐ General and/or Managing Partner
Full Name (La Sim Fass, P	ist name first, if ind 'h.D.	ividual)				
	esidence Address Therapeutics,		and Street, City, State, Zi way Center, Suite 504			
Check Box(es		☐ Promoter	☐ Beneficial Owner	☐ Executive Officer		☐ General and/or Managing Partner
Full Name (La David B. Mo	est name first, if ind Williams	ividual)				
	lesidence Address Therapeutics,		and Street, City, State, Zi way Center, Suite 504			
Check Box(es	s) that Apply:	☐ Promoter	☐ Beneficial Owner	☐ Executive Officer		☐ General and/or Managing Partner
Full Name (La Howard M.	st name first, if ind Schneider	ividual)				
	desidence Address Therapeutics,		and Street, City, State, Zi way Center, Suite 504			
Check Box(es		Promoter	⊠ Beneficial Owner	☐ Executive Officer	Director	☐ General and/or Managing Partner
Full Name (La Wood River	ist name first, if ind Trust	ividual)				
	esidence Address C. Doyle, co-tru		and Street, City, State, Zi	p Code) npany, 1410 Nemours	Building, 1007 O	range Street,

Business or Residence Address (Number and Street, City, State, Zip Code)

☐ Beneficial Owner

(Use blank sheet, or copy and use additional copies of this sheet, as necessary.)

☐ Executive Officer

Director

☐ General and/or Managing Partner

Wilmington, DE 19801

Check Box(es) that Apply:

Full Name (Last name first, if individual)

☐ Promoter

					В	. INFORM	ATION AB	OUT OFFE	RING						
1.	Has t	he issuer	sold, or do	oes the issi	uer intend	to sell, to r	on-accred	ited investo	ors in th	is offering?	•		Yes	No ⊠	
Answer also in Appendix, Column 2, if filing under ULOE.															
2.	2. What is the minimum investment that will be accepted from any individual?								\$25,000						
3.	Does	the offer	ing permit	joint owner	ship of a	single unit?							Yes ⊠	No □)
4.	4. Enter the information requested for each person who has been or will be paid or given, directly or indirectly, any commission or similar remuneration for solicitation of purchases in connection with sales of securities in the offering. If a person to be listed is an associated person or agent of a broker or dealer registered with the SEC and/or with a state or states, list the name of the broker or dealer. If more than five (5) persons to be listed are associated persons of such a broker or dealer, you may set forth the information for that broker or dealer only.								SEC ad are						
		e (Last na apital Lto		individual)											
Bus 45	siness Broad	or Reside	ence Addre	ess (Numbe w York, N	er and Stro Y 10006	eet, City, St	ate, Zip Co	ode)							
Me	rcer C	apital Ltd													
	neck "A			d Has Solice Individual S INTITION INTI		ends to Sol [CO] [LA] [NM] [UT]	Icit Purcha [CT] [ME] [NY] [VT]	sers [DE] □ [MD] □ [NC] ☒ [VA] □	[DC] [MA] [ND] [WA]	[FI] [[MI] [[OH] [[WV] [[MN] [OK]	Mj [M	AII S	tates [ID] [MO] [PA] [PR]	0000
Ful	l Name	(Last na		individual)	IN L	[01] [<u> </u>	IVOL EL	P. COL	<u> </u>		<u> </u>	·· <u>, </u>	į ry	
Bus 880	siness Third	or Reside	ence Addre , 12 th Floo	ess (Numbe r, New Yo	er and Stro r k, NY 10 0	eet, City, St	ate, Zip Co	ode)							
			d Broker o ents, Inc.	r Dealer		· · · · · · · · · · · · · · · · · · ·									
	neck "A			Has Solice Individual S INDIVID		ends to Sol [CO] [LA] [NM] [UT]	icit Purcha [CT] □ [ME] □ [NY] ☒	Sers [DE] [MD] [NC] [VA]	[DC] [MA] [ND] [WA]	[FI]	[MN]		Alisi	tates [ID] [MO] [PA]	
Full Name (Last name first, if individual)															
Business or Residence Address (Number and Street, City, State, Zip Code)															
Name of Associated Broker or Dealer															
	neck "A			d Has Solid ndividual S [AR] [KS] [NH] [TN] [TN] [TN]		[CO]	[CT]	[DE]	[DC] [MA] [ND] [WA] [WA]	[FI] [[MI] [[OH] [[WY] [] [MN]] [OK]			tates [ID] [MO] [PA] [PR] [PR]	

(Use blank sheet, or copy and use additional copies of this sheet, as necessary.)

B3043530.1 3 of 8

C. OFFERING PRICE, NUMBER OF INVESTORS, EXPENSES AND USE OF PROCEEDS

1.	alre che	er the aggregate offering price of securities included in this offering and the total amount eady sold. Enter "0" if answer is "none" or "zero." If the transaction is an exchange offering, eck this box \square and indicate in the columns below the amounts of the securities offered for hange and already exchanged.		
		Type of Security	Aggregate Offering Price	Amount Already Sold
		Debt	\$ <u>0</u>	\$ <u>0</u>
		Equity (including warrants to purchase common stock)	\$ <u>11,500,000</u>	\$2,175,000
		□ Preferred		
		Convertible Securities (including warrants)	\$ <u>0</u>	\$ <u>0</u>
		Partnership Interests	\$ <u>0</u>	\$ <u>0</u>
		Other (Specify)	\$ <u>0</u>	\$ <u>0</u>
		Total	\$ <u>11,500,000</u>	\$ <u>2,175,000</u>
		Answer also in Appendix, Column 3, if filing under ULOE.		
2.	this 504	er the number of accredited and non-accredited investors who have purchased securities in offering and the aggregate dollar amounts of their purchases. For offerings under Rule, indicate the number of persons who have purchased securities and the aggregate dollar bunt of their purchases on the total lines. Enter "0" if answer is "none" or "zero."	Number of Investors	Aggregate Dollar Amount of Purchases
		Accredited Investors	<u>48</u>	\$ <u>2,175,000</u>
		Non-accredited Investors	0	\$ <u>0</u>
		Total (for filing under Rule 504 only)		_ \$
		Answer also in Appendix, Column 4, if filing under ULOE.		
3.	sec moi	ils filing is for an offering under Rule 504 or 505, enter the information requested for all urities sold by the issuer, to date, in offerings of the types indicated, in the twelve (12) on the first sale of securities in this offering. Classify securities by type listed in the total content of the first sale of securities in this offering.		
		Type of effecting	Type of	Dollar Amount
		Type of offering Rule 505.	Security	Sold \$
		Regulation A.		\$ \$
		Rule 504.		\$ \$
		Total		\$
,	_			·
4.	sec issu	Furnish a statement of all expenses in connection with the issuance and distribution of the urities in this offering. Exclude amounts relating solely to organization expenses of the Ier. The information may be given as subject to future contingencies. If the amount of an enditure is not known, furnish an estimate and check the box to the left of the estimate.		
		Transfer Agent's Fees.	[\$ <u>1,000</u>
		Printing and Engraving Costs.	[□ \$ <u>5,000</u>
		Legal Fees		\$ <u>114,000</u>
		Accounting Fees	[\$30,000
		Engineering Fees.	[□ \$ <u>0</u>
		Sales Commissions (specify finders' fees separately)		
		Other Expenses (identify) (10% of offering proceeds to placement agents)		
		Total		
	b.	Enter the difference between the aggregate offering price given in response to Part C-Question 1 and total expenses furnished in response to Part C - Question 4.a. This difference is the "adjusted gross proceeds to the issuer."		1 4 <u>301,300</u>
				\$ <u>1,807,500</u>

4 of 8

C. OFFERING PRICE, NUMBER OF INVESTORS, EXPENSES AND USE OF PROCEEDS							
Indicate below the amount of the adjusted gross proceeds to the issuer used or proposed to be used for each of the purposes shown. If the amount for any purpose is not known, furnish an estimate and check the box to the left of the estimate. The total of the payments listed must equal the adjusted gross proceeds to the issuer set forth in response to Part C- Question 4.b. above.							
abovo.			Payments to Officers, Directors, & Affiliates	Payments To Others			
Salaries and fees		🗆 \$ <u>0</u>	1	□ \$ <u>0</u>			
Purchase of real estate		🗆 \$ <u>0</u>	!	□ \$ <u>0</u>			
Purchase, rental or leasing and inst	allation of machinery and equipment	🗆 \$ <u>0</u>	1	□ \$ <u>0</u>			
Acquisition of other business (include	dings and facilitiesling the value of securities involved in this offering the assets or securities of another issuer pursuant	🗆 \$ <u>0</u>	<u>)</u>	□ \$ <u>0</u>			
		🗆 \$ <u>0</u>		□ \$ <u>0</u>			
Repayment of indebtedness		🗆 \$ <u>0</u>	<u>)</u>	⊠ \$ <u>330,000</u>			
Working capital		🗆 \$ <u>0</u>	<u>)</u>	⊠ \$ <u>1,477,500</u>			
Other (specify):		□ \$⊆	<u>)</u>	□ \$ <u>0</u>			
Column Totals		🗆 \$ <u>0</u>	<u>)</u>	□ \$ <u>0</u>			
Total Payments Listed (column tota	ls added)	•••	⊠ \$1,807,	500			
	D. FEDERAL SIGNATURE						
following signature constitutes an undertakin	signed by the undersigned duly authorized person g by the issuer to furnish to the U.S. Securities an by the issuer to any non-accredited investor pursu	d Exchai	nge Commissio	n, upon written			
Issuer (Print or Type) Novelos Therapeutics, Inc.	Signature	ate une ⁹ ,					
Name of Signer (Print or Type) Harry S. Palmin	Title of Signer (Print or Type) President, Acting CEO, CFO						
Intentional misstatements or omissio	ATTENTION ns of fact constitute federal criminal violations	. (See 1	8 U.S.C. 1001.)				